Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02285062) enrolled 570 people with lymphoma, split into two groups of 285. One group received a drug called lenalidomide combined with a standard chemotherapy regimen known as R-CHOP (referred to as R²-CHOP), while the other group received a dummy pill (placebo) combined with the same R-CHOP chemotherapy. The trial was primarily measuring how long participants went without their disease getting worse or dying — a measure called "progression-free survival." It also tracked a number of secondary measures, including overall survival, how long people remained free of key negative events, how many achieved a complete response (where scans showed no detectable sign of disease), and how many had any measurable response to treatment. The reported data shows that for the primary outcome — progression-free survival — as well as for overall survival, event-free survival, and duration of complete response, the values were recorded as "NA" (not available) in the submitted results. This means those particular figures were not reported in the structured data submitted to ClinicalTrials.gov, so no numbers for those outcomes can be described here. For the secondary outcomes where numbers were provided, the reported data shows that 69.1% of participants in the lenalidomide plus R-CHOP group and 64.9% in the placebo plus R-CHOP group achieved a complete response — meaning scans showed no detectable sign of their lymphoma at the time of assessment. For any measurable response (either complete or partial shrinkage of the lymphoma), the reported rate was 90.9% in both groups. It is worth noting that more participants left the treatment period early in the lenalidomide group (72 people) compared with the placebo group (44 people), though the reasons for this are not detailed in the structured data provided. The reported data shows only what was measured and counted at the time of the data cut-off, and the missing figures for several key outcomes mean a complete picture is not available from this submission alone. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 39563886) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Muscular Dystrophy Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been confirmed by a tissue biopsy to have a specific type of lymphoma called Diffuse Large B-Cell Lymphoma (Activated B-Cell type)
- You have been recently diagnosed with this lymphoma and have not yet received any treatment for it
- Your lymphoma can be seen and measured on a CT or MRI scan
- You are generally able to carry out daily activities with little to no limitation (your doctor will assess this using a standard scale)
- You are between 18 and 80 years old; if you are over 80, you may still be considered if you are in good general health and your doctor agrees
Who may not be able to join:
- You have a different type of lymphoma other than Diffuse Large B-Cell Lymphoma
- You have had another type of cancer in the past, unless you have been cancer-free for 5 or more years
- You have HIV, Hepatitis B, or Hepatitis C, or have tested positive for any of these infections
- You have a heart condition where your heart is not pumping efficiently enough (below 45%), or you have moderate-to-severe nerve damage causing weakness or numbness (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Kaplan-Meier Estimate of Progression Free Survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.